Previous 10 | Next 10 |
Are These 3 Penny Stocks Worth Buying During the Meme Stock Frenzy? While popular penny stocks come around regularly, ones that make triple-digit gains in a short time frame do not. And, this is the case right now with Camber Energy Inc. ( NYSE: CEI ). In the past month, CEI stock h...
- Conference Dates: September 13 th -15 th - RALEIGH, NC / ACCESSWIRE / September 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato is scheduled to prese...
- Conference Dates: September 08 th -10 th - RALEIGH, NC / ACCESSWIRE / September 1, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will be participating...
3 Biotech Penny Stocks For Your September Watchlist Are biotech penny stocks worth buying? This is a question that many penny stocks investors wonder about, and the answer is quite clear. Depending on what type of trader you are and what your tolerance for volatility is, biotech p...
GeoVax Labs (NASDAQ:GOVX) +75% presents COVID-19 vaccine data at the European Society of Medicine (ESMED) General Assembly Marin Software MRIN +25% integrates with Criteo's ecommerce media platform for advertising SunLink Health Systems (NYSE:SSY) +12%. The9 NCTY +9% ...
Enlivex Therapeutics ENLV +22% to launch Phase IIb Allocetra trial for COVID-19 patients in Israel ADMA Biologics ADMA +17% on FDA approval for plasma collection facility in Maryville, TN Travere Therapeutics TVTX +17% meets primary efficacy endpoint in late-stag...
-Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence reported previously in Journal of Clinical Investigation detailing larazotide's me...
- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4 2021 - - Acquired humanized anti-GIP (glucose-dependent insulinotropic polypeptide)...
Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate in the Biopharma Spotlight Series: Innovation in GI Conference Call hosted by Gary Nac...
4 Penny Stocks For Your Watchlist Right Now With a new month around the corner, there are plenty of penny stocks that investors are watching right now. This includes a specific spotlight on tech and biotech penny stocks . One thing to consider when investing in penny stocks in 2...
News, Short Squeeze, Breakout and More Instantly...
9 Meters Biopharma Inc. Company Name:
NMTR Stock Symbol:
NASDAQ Market:
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President ...
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2...
RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the r...